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and synthesizing evidence from existing research in such a way 
as to minimize the risk of bias and maximize transparency when 
summarizing what is already known in relation to answering a 
research question (Jadad et al., 1996). The methodology of sys-
tematic reviews was developed in the field of clinical research in 
humans (Scholten et al., 2005) but is increasingly being applied 
in the fields of toxicology and environmental health (Rooney et 
al., 2016; Woodruff and Sutton, 2014; Vandenberg et al., 2016) 
to collect data from the scientific literature for applications such 
as risk assessment in a more structured, transparent, and unbi-
ased way.
So far, these two developments have taken place independent-
ly. However, although the concepts of AOPs and evidence-based 
methods are not directly linked, they may be mutually reinforc-
ing. AOPs are a useful framework to organize and assess mech-
anistic evidence in risk assessments. For instance, a body of in 
vitro evidence may be considered less indirect or externally more 
1  Introduction
Two relatively new developments in the field of toxicology and 
environmental health are the development and use of adverse 
outcome pathways (AOPs) (Villeneuve et al., 2014) and the ap-
plication of evidence-based approaches such as systematic re-
views (Griesinger et al., 2008; Hoffmann et al., 2017; Stephens 
et al., 2016; Whaley et al., 2016) and systematic evidence maps1 
(Wolffe et al., 2019). An AOP describes a sequence of temporal-
ly and causally linked events at different levels of biological or-
ganization, which follows exposure to a stressor (e.g., chemical, 
physical, etc.) and leads to an adverse health effect in humans or 
wildlife. AOPs are used to organize mechanistic information and 
support the application of mechanistic data in chemical safety as-
sessment (Groh et al., 2015). A systematic review can be defined 
as a process of systematically searching, selecting, appraising, 
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1 Systematic reviews are designed to test specific hypotheses and are focused on narrowly defined questions, whereas systematic maps are more exploratory.  
   Systematic maps are summaries of what the existing research is, not what it says.
The workshop “Application of evidence-based methods to construct mechanistic frameworks for the development and 
use of non-animal toxicity tests” was organized by the Evidence-based Toxicology Collaboration and hosted by the 
Grading of Recommendations Assessment, Development and Evaluation Working Group on June 12, 2019. The purpose 
of the workshop was to bring together international regulatory bodies, risk assessors, academic scientists, and industry 
to explore how systematic review methods and the adverse outcome pathway framework could be combined to develop 
and use mechanistic test methods for predicting the toxicity of chemical substances in an evidence-based manner. The 
meeting covered the history of biological frameworks, the way adverse outcome pathways are currently developed, the 
basic principles of systematic methodology, including systematic reviews and evidence maps, and assessment of cer-
tainty in models, and adverse outcome pathways in particular. Specific topics were discussed via case studies in small 
break-out groups. The group concluded that adverse outcome pathways provide an important framework to support 
mechanism-based assessment in environmental health. The process of their development has a few challenges that could 
be addressed with systematic methods and automation tools. Addressing these challenges will increase the transparency 
of the evidence behind adverse outcome pathways and the consistency with which they are defined; this in turn will 
increase their value for supporting public health decisions. It was suggested to explore the details of applying systematic 
methods to adverse outcome pathway development in a series of case studies and workshops.
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2 Background on AOPs, evidence-based approaches  
and GRADE
2.1  EBTC and evidence-based approaches
Dr Katya Tsaioun, director of the Evidence-based Toxicolo-
gy Collaboration at Johns Hopkins Bloomberg School of Pub-
lic Health, introduced EBTC as a collaboration of internation-
al stakeholders in toxicology and risk assessment, bound by the 
same vision of bringing evidence-based methods to the field and 
making them the standard used in risk assessment. Dr Tsaioun in-
troduced the topic of the workshop, stressing that the AOP frame-
work was a significant contribution to developing a transparent, 
reproducible framework for risk assessment of chemicals that al-
lows for modernization of the regulatory testing paradigm. The 
AOP framework allows incorporation of advancements in the 
understanding of toxicological mechanisms and thus addresses 
some of the challenges and barriers that exist in integrating new 
science into toxicology and risk assessment. These challenges in-
clude uncertainty in assumptions about biological mechanisms 
and the tests that provide information on these mechanisms, and 
they are particularly important in the regulatory environment, 
where certainty in the results is paramount to make decisions 
about human and environmental health.
Dr Tsaioun then stressed that the mode of action (MoA) 
frameworks in the field of drug development offer an example 
for toxicologists. The concept of MoA (Fig. 1) has been in use in 
pharmacology for many decades and is at the start of every drug 
discovery program in which a molecular target is identified, val-
idated and de-risked (Tsaioun, 2010). This mechanistic knowl-
edge is then traced to higher levels of organization such as cel-
lular effects, organ effects, and whole organism effects. In phar-
macology, the aim is to find molecules with a desirable effect on 
the body to stop or modify a disease, whereas in toxicology the 
valid (compared to evidence from animal studies) if that evi-
dence is linked to an AOP. However, the process of assembling 
and evaluating the mechanistic information behind an AOP is re-
liant on expert knowledge and could be strengthened significant-
ly with systematic methodologies as a foundation. Hence, sys-
tematic methods could be used here to an advantage to make the 
origination, development and use of AOPs more objective and 
reliant on the wide body of literature, while still relying on ex-
perts in the field for interpreting the data. 
In order to explore if and how AOPs and evidence-based meth-
ods could work together, the Evidence-Based Toxicology Col-
laboration (EBTC) held a workshop, in collaboration with the 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group on June 12, 2019 at Mc-
Master University in Hamilton (Ontario), Canada. The workshop 
preceded the annual GRADE meeting on June 13-14. 
The goal of the workshop was to discuss, via four related 
themes, how systematic review methods and AOP concepts can 
be combined to develop and use mechanistic evidence and new 
approach methodologies (NAMs) for predicting the toxicity of 
chemical substances in an evidence-based manner. More specifi-
cally, the workshop addressed these four questions:
1. How do scientists distinguish high quality in vitro studies 
from low quality ones? 
2. What would a systematic approach to the development of 
AOPs look like? 
3. How does one assess the certainty in AOPs, i.e., distinguish 
spurious AOPs from plausible ones? 
4. How can AOPs inform the development of NAMs?
The workshop consisted of six expert plenary topic introduc-
tions2, followed by break-out sessions per theme co-led by ple-
nary speakers and EBTC researchers. Thirty-four researchers 
from academic institutes and regulatory agencies participated.
2 The full recording of the workshop can be found on the YouTube channel of EBTC (https://youtu.be/NNa0r2qL4pI; accessed 28.01.2021).
Fig. 1: Mode of action (MoA) pathway
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7. Integrate the evidence found (qualitatively or quantitatively 
(as a meta-analysis)).
In short, systematic reviews are produced using a structured 
framework that assures transparency, objectivity and compre-
hensiveness. Such approaches are critical in regulatory settings, 
which is the reason for many agencies around the world, such 
as European Food Safety Authority (EFSA, 2010), National 
Toxicology Program at the National Institute of Environmental 
Health and Sciences (NIEHS) (Rooney et al., 2014; Thayer et 
al., 2014) and US Environmental Protection Agency (US EPA) 
(EPA, 2018), to adapt the systematic review frameworks for their 
assessments.
Systematic methodology could potentially also be used to de-
velop and assess the certainty in an AOP and subsequently define 
and find the appropriate evidence that corresponds to specific 
MIE, KE, and especially the relationships between them (KER), 
in the process (Fig. 2). New AOPs are created in the AOP-Wi-
ki, which serves as an international AOP repository. Currently, 
AOPs may be proposed by any researcher and may be listed as 
“under development: contributions and comments welcome” 
(OECD, 2017a). This method of soliciting expert knowledge 
into the AOP-Wiki, while making the initiation of a new AOP 
and comments on existing projects more democratic, could ben-
efit from refinement to make sure that these initial contributions 
are evidence-based and are within the scope and feasibility of the 
AOP framework. Hence, work needs to be done to make it pos-
sible for the AOPs to be transparently and objectively updated 
as new biological KEs and pathways are discovered. Many of 
these questions have been wrestled with and solved in systematic 
frameworks developed in order to objectively summarize clini-
cal research, and the AOP community can capitalize on these ad-
vancements to increase the objectivity, transparency and repro-
ducibility of their work products.
Dr Tsaioun noted that there are many new ML- and AI-based 
tools that are currently being tested and validated for the most la-
bor-intensive parts of systematic reviews such as literature search 
and screening (Howard et al., 2016; Tsafnat et al., 2013; Van der 
Mierden et al., 2019). The remaining challenge now is to trans-
goal is to detect potential adverse effects of stressors such as en-
vironmental pollution, industrial chemicals, etc.
The AOP framework (Fig. 2) builds on the MoA concept 
(Meek, 2014). This framework consists of the molecular initiating 
event (MIE) and a series of cellular and tissue-level key events 
(KEs) that eventually lead to specific adverse outcomes (AO) on 
the organ and/or organism levels. This framework has been devel-
oped (Villeneuve et al., 2014) as a way to organize information, 
in particular for the regulatory environment, where certainty, rig-
or and reproducibility are necessary. However, Dr Tsaioun noted 
that our knowledge is constantly evolving and that there are large 
gaps in our current understanding of biology. Systematic meth-
ods, especially with the advent of machine learning (ML) and ar-
tificial intelligence (AI) techniques, have a potential to find such 
gaps and identify areas where scientific research may be directed, 
while doing so with transparency and minimal bias.
Systematic methodologies, including systematic maps and 
systematic reviews, aim to help assemble the current knowledge 
on a topic in an objective, comprehensive and transparent man-
ner. The difference between a classical, narrative review and a 
systematic review lies in their structure. Narrative reviews are 
written by one or more experts, and are based on their opinions, 
expertise, and frequently an informal selection from the litera-
ture that they are familiar with. Systematic reviews, on the other 
hand, follow specific steps, starting with a specifically formulat-
ed research question (Morgan et al., 2018). Most systematic re-
views are structured around a PECO/PICO (Population, Expo-
sure/Intervention, Comparator and Outcomes) question, which 
determines the inclusion and exclusion criteria and the strategy 
for the literature search.
The following are the main steps of the systematic review:
1. Identify a problem.
2. Formulate a specific PECO/PICO question.
3. Write and publish the protocol.
4. Search the evidence in the literature as broadly as possible.
5. Apply protocol-defined inclusion and exclusion criteria to 
screen the relevant literature. 
6. Assess the risk of bias of the collected evidence. 
Fig. 2: Adverse outcome pathway (AOP) framework
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er in the majority of cases, as opposed to the BH considerations, 
where reasons to increase certainty are sought.
Dr Schünemann said there is still work to be done to devel-
op GRADE, specifically with regard to the indirectness domain, 
which is also an important consideration in relation to AOPs. The 
indirectness domain assesses the extent to which the evidence 
found reflects the population, intervention and outcomes of inter-
est. GRADE has begun using AOPs to fill some of the gaps that 
exist in the indirectness domain as well as considerations regard-
ing biological plausibility. The key take-home message in regard 
to AOPs, he said, is that AOPs mainly enable researchers to ask 
the right questions. For example, AOPs allow researchers to ex-
plore whether or not there is a direct connection between chemi-
cal exposure and adverse outcomes and support some judgments 
of indirectness. These provide the rationale to move to human 
studies and evaluate human evidence. 
2.3  Modeled evidence
Dr Jan Brożek, associate professor in the Department of Health 
Research Methods, Evidence and Impact at McMaster Universi-
ty, proposed that the models used by researchers need to be for-
malized and become quantitative mathematical representations 
of reality. Models may be simple or much more complex, such 
as economic models and system dynamics in infectious diseases. 
Scientists and regulators alike need to be able to assess the cer-
tainty, or the quality, of the outputs.
“Certainty of evidence” refers to how much the results can be 
trusted and how much the results can help provide evidence in 
decision-making. There are three levels on which this may be as-
sessed: (1) certainty in the inputs, (2) certainty in the model it-
self, and (3) certainty of the output from the model. “Certainty of 
modeled evidence” refers to the output and is the most important 
piece for decision-making. In order to assess this, it must be un-
derstood how certain researchers are about inputs and how cer-
tain they are about the model.
Given any piece of evidence, Dr Brożek said, there are fac-
tors that increase or decrease how much it can be trusted. The 
five factors used within GRADE that decrease certainty are: risk 
of bias, indirectness, inconsistency, imprecision and publica-
tion bias (Morgan et al., 2016b). The three factors that increase 
certainty are: large effect, dose response and opposing residual 
confounding.
The criteria that an ideal model needs to include should be 
generated first, and then existing models should be systemati-
cally searched to find one as close as possible. If such a model is 
not found, a novel model must be developed, or modeling must 
be forgone. 
Choosing a model implies making certain assumptions, the 
most important of which is whether the new model can be as-
sessed to be better than existing models. If there is an existing 
model, certainty of outputs must be addressed; this certainty is 
form the semi-automated processes into fully automated search 
and literature screening and data extraction tools. Eventually, 
these tools will enable a systematic review process that can be 
updated in real time as new information becomes available. This 
will be highly valuable for applying evidence-based approaches 
to the development and evaluation of AOPs and mechanistic tests 
that measure KEs in the framework.
2.2  GRADE
Dr Holger Schünemann, chair and professor in the Department 
of Health Research Methods, Evidence and Impact at McMas-
ter University, provided background on the GRADE framework 
and its applicability for assessing the certainty in AOPs. GRADE 
was established 20 years ago as an informal collaboration of peo-
ple with an interest in addressing the shortcomings of assessment 
of confidence of various treatments in healthcare. GRADE has 
developed a practical and transparent approach to grading qual-
ity (or certainty) of evidence and strength of recommendations 
and is now considered the standard in the development of clinical 
practice guidelines. GRADE, which has 16 centers and networks 
around the globe to support users, is now used by more than 100 
organizations around the world. GRADE is the method used in 
Cochrane3 systematic reviews to assess certainty in the evidence 
that has been synthesized to answer a research question. GRADE 
is also used for the development of recommendations by an in-
ternational group of diverse contributors from different back-
grounds, including many public health professionals. 
Although for many years the Bradford Hill (BH) criteria, de-
veloped in the 1960s (Hill, 1965) and then iterated by David 
Sackett and his colleagues (Guyatt et al., 1984; Tugwell et al., 
1985), were considered the gold standard for assessing causality 
in epidemiology research, Dr Schünemann argued that over time 
this approach has become outdated. For example, publication 
bias (selective publishing of data, resulting in a skewed repre-
sentation of a phenomenon in the published literature, e.g., a bi-
as towards publishing positive toxicological outcomes) was not 
part of the criteria; and the criteria were not completely thought 
through with respect to association (rather than causation), the 
impact of interventions, and prognosis. These shortcomings 
have prevented the BH criteria from being used in exposure as-
sessments. GRADE was developed to address these shortcom-
ings (Schünemann et al., 2011). Additionally, GRADE has been 
extended to provide context for decision-making in the evi-
dence-to-decision frameworks (Parmelli et al., 2017). 
One important question during development of the GRADE 
framework was whether to focus on factors that make users more 
confident in a body of evidence or on factors that make them less 
confident. GRADE chose the latter approach, in which scientists 
look at scenarios in which confidence is high and then try to de-
termine what factors could cause users to lose confidence in the 
evidence. This approach was selected as it was found to be easi-
3 Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health formed to organise medical research  
   findings to facilitate evidence-based choices about health interventions. A Cochrane Review is a systematic review of research in health care and health  
   policy conducted according to the guidelines developed by Cochrane and these reviews are internationally recognized as the highest standard in evidence-based  
   health care (https://www.cochranelibrary.com/about/about-cochrane-reviews).
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terms before labeling extracted information as the same. Second, 
humans must then train computers to digitize this information 
using controlled vocabularies (such as Universal Medical Lan-
guage System). However, while these “digital” vocabularies in-
clude definitions and synonyms, they lack the relationships be-
tween terms found in ontologies that are needed to identify con-
nections between exposure and effect findings that might have 
otherwise been missed. Dr Angrish concluded that mapping the 
digitized data using an AOP ontology model is a possible solu-
tion (and an active area of research) with the added advantage 
that this approach combines expert- and data-driven evidence in-
tegration within an AOP framework.
2.5  Assessing risk of bias of in vitro studies
Dr Andrew Rooney, the acting director of the Office of Health 
Assessment and Translation (OHAT) at the National Toxicolo-
gy Program (NTP), discussed the “Risk of Bias Appraisal of In 
Vitro Studies.” His presentation focused on study quality or risk 
of bias appraisal for in vitro studies – a type of study that obvi-
ously forms an important part of the mechanistic studies that may 
be considered within an AOP.
There are four major aspects to be considered in the critical ap-
praisal of any study:
– Internal validity (risk of bias): whether the study design and 
conduct may bias the results.
– External validity (applicability/generalizability): the extent to 
which the study addresses the research question or the review 
question.
– Reporting quality: the adequacy of reporting of the design, con-
duct and results of a study. This may be independently assessed 
or addressed as part of the assessment of internal validity.
– Sensitivity: whether or not the study design impacts the abili-
ty of that study to detect an effect (i.e., if only high doses were 
used and low doses are of interest, it will not be relevant to 
your research question).
In addition to the apical endpoint studies that need to be critically 
appraised, mechanistic data also need to be analyzed. Mechanis-
tic data generally focus on upstream indicators and may be part 
of a larger study that investigated the health effect of chemical 
exposure, but the data are needed to illuminate the AOP. Mecha-
nistic data can be found from a wide variety of study types: ani-
mal or human in vivo studies, in vitro studies of either animal or 
human cells, in silico or modeled data.
In terms of assessing risk of bias, existing approaches for in 
vivo study designs are effective. A number of tools have been de-
signed to evaluate experimental animal studies including, but 
not limited to, the SYRCLE tool (Hooijmans et al., 2014), the 
Navigation Guide (Lam et al., 2014), and the NTP/OHAT tool 
(Rooney et al., 2014). As regulators are shifting towards using 
more in vitro studies, new tools and approaches are currently be-
ing developed as the approaches for in vivo studies are not fully 
applicable. Prominent approaches include the NTP/OHAT “use 
case”4, Science in Risk Assessment and Policy (SciRAP) (cur-
dependent on the inputs of the model and the model itself. It is 
due to these assumptions that GRADE suggests using systematic 
searching to find existing models instead of developing models. 
Creating a custom model with every interaction known includ-
ed would be ideal, but toxicology as a field has many unknowns, 
which makes it difficult to create a model from scratch. 
In summary, Dr Brożek proposed the following four steps in 
choosing a model:
– Perform a systematic literature search with specific search cri-
teria.
– Choose the “best” model and use it as is.
– If this is not possible, adapt an existing model that you believe 
will be the best. 
– If no existing model exists, then build your own model. 
Further work is necessary to develop the tools to determine the 
certainty in a model (Brozek et al., 2021).
2.4  Systematic maps
Dr Michelle Angrish, a toxicologist at the US Environmental Pro-
tection Agency, provided an overview of “Systematic Maps and 
Literature-Driven AOP Development.” Dr Angrish stressed that 
systematic methods could be leveraged to support a more da-
ta-driven approach to mechanistic evidence integration using an 
AOP framework. Dr Angrish described the AOP analytical con-
struct and how it is currently used to link a sequential chain of 
causally linked events at different levels of biological organization 
using the AOP components MIE, KE, KER, and AO, according 
to the Organisation for Economic Cooperation and Development 
(OECD) guidance (OECD, 2017a). The current AOP development 
approach is primarily an expert-driven process that could benefit 
from systematic methods, particularly with respect to increasing 
transparency and reproducibility. In particular, researchers could 
use evidence-based systematic methods to explore direct and indi-
rect connections between outcomes of regulatory concern and the 
AOP analytical construct (i.e., KE-KER(s), etc.).
Dr Angrish next introduced systematic review methods in en-
vironmental health sciences and provided an example of how 
systematic review workflows and systematic mapping methods 
could be used to formulate a literature search, screen studies, and 
extract data (i.e., test system/species, exposure methods, exper-
imental design, endpoints, chemicals, etc.). In the example, Dr 
Angrish demonstrated how the overall workflow could be formu-
lated around a particular molecular target and outcome of inter-
est. Experimental studies and extracted data organized into liter-
ature inventories can be mapped to the AOP schema, but a chal-
lenge lies in the semantics. 
These inventories of environmental effect findings preserve 
the original written language as reported in the PDF documents, 
which presents a natural language processing challenge for sev-
eral reasons. First, natural language is not machine-readable, 
making it difficult to make information automatically interoper-
able. Natural language requires humans to first sort out redun-
dant or ambiguous (homonyms, polysemes, homophones, etc.) 
4 Protocol to evaluate the evidence for an association between perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) exposure and immunotoxicity.  
   https://ntp.niehs.nih.gov/ntp/ohat/pfoa_pfos/protocol_201506_508.pdf 
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hazard to humans, upgraded to being “known” if they are confi-
dent in the other evidence, or downgraded to “suspected” if they 
have less confidence.
EBTC has been working with OHAT and other stakeholders on 
harmonizing such agency-specific approaches based on the fun-
damental principles of systematic review, as summarized in the 
primer by Hoffmann et al. (2017). The authors of this primer rep-
resent major stakeholders in the field of toxicology, risk assess-
ment and systematic review communities. There are a number of 
projects EBTC is coordinating and co-leading that focus on risk-
of-bias of in vitro studies, done in collaboration with OHAT, US 
EPA, EFSA and other stakeholders.
2.6  Integrated approaches to testing and assessment
The plenary session was concluded by Dr Patience Browne, a 
policy analyst in the Test Guidelines Programme at the OECD, 
who discussed “IATA and Alternative Approaches Based on 
AOPs”. Though, as Dr Browne indicated, AOPs are a relatively 
recent concept in the field of toxicology, they are an evolution of 
the preceding “mode of action” and “toxicity pathway” concepts 
useful for organizing diverse data in a codified way. The AOP 
framework also can be applied to map test guideline endpoints 
used to test the toxicity of a chemical to KEs in order to build 
predictive models, develop integrated approaches to testing and 
assessment (IATA), and guide logical next steps (or draw conclu-
sions) for evaluating chemical safety (OECD, 2016).
IATAs range from highly flexible, informal approaches that rely 
heavily on expert judgement to prescriptive, structured approaches 
that rely on pre-defined rules to reach conclusions. Once the flex-
ibility of an IATA has been removed and the information sourc-
es (e.g., in silico, in chemico, in vitro, in vivo methods) and data 
interpretation procedures are fixed, the IATA becomes a defined 
approach (DA) (OECD, 2017b). In a DA, expert judgement is re-
moved and independent users of the DA should come to the same 
conclusion for the same chemical. A “complete” AOP (including a 
MIE, all KEs, all KERs, and an AO) is not necessary for IATA de-
velopment. Rather, the appropriate degree of completeness of the 
AOP will vary highly with the problem formulation. Three exam-
ples were provided to illustrate how AOPs can be used to guide 
IATA development under different circumstances.
In the first example, Dr Browne discussed human skin sensi-
tization, which is a relatively simple and well-understood toxi-
cological process supported by a complete AOP, with multiple 
guideline methods that measure all KEs. There are also approxi-
mately 130 chemicals with data from multiple in vitro assays, in 
vivo mouse assays, and humans (Hoffmann et al., 2018). Collec-
tively, this information has been used to develop DAs to predict 
with high sensitivity, specificity and accuracy the rodent and hu-
man skin sensitization response from in silico and in vitro data 
(Kleinstreuer et al., 2018). The non-animal methods combined 
in DAs are sufficiently predictive that results of DAs are accept-
ed as replacements for animal data in some regulatory contexts 
(e.g., US EPA). 
rently in a pilot phase) (Molander et al., 2015), the EPA/IRIS 
Handbook and NTP (Rooney et al., 2014) approaches. 
The OHAT approach (originally established and published for 
human studies and laboratory animal toxicology studies) begins 
with a set of ten basic questions and an eleventh question ad-
dressing additional threats to validity:
1. Was administered dose or exposure level adequately random-
ized?
2. Was allocation to study groups adequately concealed?
3. Did selection of study participants result in the appropriate 
comparison groups?
4. Did study design or analysis account for important confound-
ing and modifying variables?
5. Were experimental conditions identical across study groups?
6. Were the research personnel blinded to the study group 
during the study?
7. Were outcome data complete without attrition or exclusion 
from analysis?
8. Can we be confident in the exposure characterization?
9. Can we be confident in the outcome assessment?
10. Were all measured outcomes reported?
11. Were there no other potential threats to internal validity?
The study design determines which questions are applicable. The 
evaluation is endpoint-specific (so the questions are answered 
multiple times for studies with multiple endpoints), and the rat-
ing is on a 4-point scale.
In order to apply the OHAT risk of bias approach to in vitro 
studies, the criteria needed to be adapted4. The overall goal was 
to consider all of the different evidence streams in a parallel man-
ner and adapt their concepts within a risk of bias approach. Fol-
lowing many iterations, NTP was able to develop a new model 
that mimicked the original OHAT 10+1 risk of bias questions. 
Consider, for example, Question 1: “Was the administered 
dose randomized?” In human and animal studies, this ques-
tion is easy to answer. In an in vitro study, researchers need to 
see whether the dose was given selectively to individual cells 
or tissues. Each cell needs to have an equal chance of being 
assigned to each study group. If a homogeneous cell suspen-
sion was used, then, by definition, there is no variation, and, as 
such, Question 1 will either not apply or indicate that there is a 
low risk of bias.
Even though the focus has been on risk of bias, there are oth-
er concerns to address with a study appraisal tool, including ex-
ternal validity. In environmental health, animal and human data 
need to come together in order to reach a hazard and risk deci-
sion. A combination of both bodies of evidence allows scientists 
to look at human observational studies to find a potential hazard 
and then use animal models to demonstrate causation. In the risk 
assessment context, it has been common to combine human and 
animal studies in this way.
In the OHAT method, mechanistic data, including in vitro 
studies, are considered together to inform the biological plausi-
bility. Scientists may conclude that the chemical is a “presumed” 
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3.1  Application of risk of bias tools to a study
This group worked through a case study where they applied the 
OHAT Risk of Bias (RoB) tool4 to a single study, also compar-
ing it with the SciRAP tool (Molander et al., 2015; Beronius et 
al., 2018), the only other generalized tool currently available 
for assessing RoB of in vitro studies. Participants were provid-
ed with a copy of the study to be assessed and a copy of the 
OHAT RoB tool prior to the meeting. Many participants were 
already familiar with RoB in general, as well as with the chal-
lenges in applying RoB to in vitro studies. The practical experi-
ences of the participants, including the use of SciRAP and the 
US EPA IRIS approach, were shared at the start of the break-out. 
Applying the individual criteria from the OHAT RoB tool often 
prompted more general discussions about, for example, the rel-
evance of these criteria for critical appraisal of in vitro studies, 
the role of in vitro studies in a risk assessment context and there-
fore the importance of performing a full RoB assessment, etc. 
A clear and recurring theme throughout the break-out was the 
difficulty in developing a “one-size-fits-all” type of approach 
that addresses all aspects of study validity for all types of in vi-
tro studies and can be easily recognized/employed by both sys-
tematic review methodologists and bench scientists. The range 
of methodological aspects that could be associated with the po-
tential for systematic error (risk of bias) was considered broad. 
Moreover, some methodological aspects were not regarded as 
internal validity, but rather as construct or external validity (not-
ing that terminology is not well-defined or consistently recog-
nized among practitioners). There was consensus, however, that 
multiple aspects were important to assessing overall validity – 
and trying to fit these into a RoB tool focused only on internal 
validity was difficult and likely to be insufficient for the needs 
of a practitioner. Furthermore, the need to assess aspects other 
than internal validity on an individual study basis introduces the 
need for refined workflows, as these aspects are not commonly 
accounted for (on an individual study basis) in a standard sys-
tematic review process. Various approaches were discussed to 
address this issue, including the use of inclusion/exclusion cri-
teria, as well as signaling and prompting questions. The break-
out group agreed, however, that flexibility to the topic, level of 
granularity, and the decision of when to do a RoB on in vitro 
data were important concepts to consider. There was also con-
sensus on the importance of subject matter expertise in refining 
questions, conducting appraisals, and resolving conflict. In clos-
ing, the workgroup recognized that available tools have a fair bit 
of overlap within elements of internal validity, but more meth-
od development and practical experience is needed to refine and 
develop new tools and processes for assessing (all aspects of) 
the validity of in vitro studies in a systematic review.
3.2  Building evidence-based AOPs
The discussion focused on building AOPs in an evidence-based 
way. To that end, the participants were presented with the AOP 
concept and schema and then discussed what sort of information 
should be sought if AOPs were to be constructed using a liter-
ature-driven (rather than expert-driven) approach. Major chal-
In the second example Dr Browne described, AOPs are used 
to help organize and integrate data for evaluating endocrine 
disruptors. International regulatory requirements for demon-
strating the endocrine disrupting potential of a chemical vary 
by region, but all include linking an adverse effect to an endo-
crine MoA. As most available methods do not measure both 
of these types of data in a single assay, evaluating endocrine 
activity requires integrating evidence from multiple assays. 
While there are very few “complete” AOPs for endocrine dis-
ruption, the MIEs and early KEs are well understood for sex 
steroid signaling pathways. The US EPA developed an estro-
gen receptor model based on data from 18 orthogonal in vitro 
assays that measure interactions with the estrogen receptor at 
various points in the signaling pathway using different tech-
nologies (Judson et al., 2015). The predictivity of the model 
has been evaluated using in vitro and in vivo reference chemi-
cals and is sufficiently reliable to screen chemicals for in vitro 
activity, prioritize chemicals for further testing, and replace the 
requirement for the rodent uterotrophic bioassay data (Browne 
et al., 2015; Kleinstreuer et al., 2016). 
The third example was an integrated approach for evaluating 
chemicals with respect to human carcinogenicity hazard. From 
a retrospective analysis of human carcinogens identified by the 
International Agency for Research on Cancer, 10 key charac-
teristics were proposed for identifying and grouping mechanis-
tic data to assess potential carcinogens (Smith et al., 2016). The 
key characteristics were not identified or organized using AOP 
frameworks, and, in fact, building “complete” AOPs or AOP 
networks to capture the various MIEs and KEs represented by 
the key characteristics would take years. Nonetheless, the key 
characteristics provide information on several levels of biolog-
ical organization, and along with animal experimental and hu-
man epidemiological data, can be organized using an AOP con-
struct without understanding all intermediate events or causal 
relationships. Such an approach has been proposed as a way 
to organize mechanistic data to predict therapeutic response of 
personalized cancer therapies (Morgan et al., 2016a). 
These three examples range from a complete AOP, to a “par-
tial” AOP with well-understood MIEs and early KEs, and a 
complex, multi-factorial pathway network of (in most cases) 
poorly understood events that lead to adverse outcomes. In 
these three examples, the ability to predict outcomes, replace 
the need for additional testing, or prioritize chemicals for ad-
ditional testing vary. In general, the more complete the AOP 
or the greater the understanding of the underlying biology, the 
more confidence there is for predicting adverse responses from 
earlier KEs. However, an AOP framework can be useful for in-
tegrating evidence, even for circumstances in which the AOP is 
largely undescribed.
3  Break-out groups
Following the presentations, participants divided into four break-
out groups to discuss the four workshop themes in more detail. 
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far. The group observed that the benefits of systematic review 
and GRADE criteria for assessing certainty in an AOP seem in-
tuitively applicable, could be of significant benefit, and there-
fore should be further explored. In addition to AOP development, 
the OECD approval process for AOPs could potentially benefit 
from the transparency and consistent operationalization of the 
GRADE approach as well.
3.3  Certainty in AOPs
The discussion’s purpose was to examine criteria on which to 
base the assessment of the certainty of evidence used in AOPs. 
It was noted that in order to comprehensively understand one’s 
certainty in the MoA depicted in an AOP framework, certain-
ty in the framework depends on the underlying evidence used 
to establish each KER. Using example AOP frameworks re-
lated to diabetes and bladder cancer, the group discussed pro-
cesses to provide structure and transparency to the presenta-
tion of AOPs, and to qualify the uncertainty of the evidence for 
KERs within an AOP. Participants considered two approaches 
for structuring the AOP development and evaluation process: a 
top-down approach and a bottom-up approach. Both process-
es consider the overarching research question, identifying the 
population, exposure, comparison, and outcomes of interest 
(PECO), as well as any available evidence that can be used to 
inform the framework (e.g., peer-reviewed publications, me-
ta-data, public databases, AOP-Wiki, etc.) at the KER level or 
across several KERs. Participants emphasized the importance 
of transparency throughout the process for evaluating certain-
ty within AOPs, especially when there is limited or no evidence 
between KE pairs. 
When understanding the certainty of the underlying evi-
dence, the perspective of the end-user should be taken into ac-
count: Does the certainty relate to the entire AOP model in order 
to inform questions about an exposure/population outcome re-
lationship or to elements within the AOP to understand the un-
certainty of a relationship between KEs? When considering the 
relationship between KEs, participants established the following 
elements for assessment: study limitations (RoB), inconsisten-
lenges to applying GRADE practitioners’ experience in liter-
ature-driven approaches to the AOP context include the use of 
a different technical vocabulary by AOP developers (e.g., MIE, 
KE, essentiality) and GRADE practitioners (e.g., evidence pro-
file, inconsistency, indirectness), and the processes by which an 
AOP is formalized. AOP development involves the use of spe-
cialized vocabulary that is not necessarily intuitive to an exter-
nal audience, partly because it relates to the technical governance 
processes by which AOPs are reviewed and approved. Also, 
AOP review and approval involves a process that is not clearly 
transparent to the GRADE practitioner, because it does not in-
volve methods that are obviously reproducible and explicitly de-
veloped to minimize the potential RoB in assembling and inter-
preting the evidence. The key concepts from the AOP technical 
vocabulary (e.g., KER, essentiality and biological plausibility) as 
well as the key steps in the development and use of AOPs (e.g., 
submission to and assessment in the OECD AOP-Wiki) were dis-
cussed. Since indirectness is one of the GRADE domains for as-
sessment of certainty, there was an intuition in the group that the 
GRADE framework might be applicable in the AOP space; how-
ever, developing a comprehensive and precise understanding of 
the AOP development process, concepts and vocabulary seems 
essential if progress is to be made.
A key conclusion from the group discussion was related to 
the fundamental unit of an AOP – the KER. Since relationships 
between KEs should be evaluable in the same way as an expo-
sure-outcome pair (both are putatively causally-related pairs of 
events), an AOP should be evaluable in the same way as the ex-
posure-outcome relationships from conventional systematic re-
views. If so, then putative AOPs could be treated as a series of 
systematic reviews of KERs, with certainty evaluated using a 
suitably adapted GRADE approach for each event-event link. 
Certainty in the overall AOP would be a function of certainty 
in each individual KER (illustrated in Fig. 3; cf. Collier et al., 
2016).
The AOP development process does not currently require use 
of systematic review methods, nor have any systematic review 
approaches been noted in the AOPs submitted for review thus 
Fig. 3: Schematic putative AOP (proposed by Fernando Nampo) displaying estimated certainty in key event relationships (from 
the molecular initiating event, MIE, through key events, to adverse outcome, AO), evaluated for certainty using the GRADE 
framework (each + symbol representing level of certainty, with + being lowest and ++++ being highest)
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4  Plenary concluding discussion
Due to the requirements of the regulatory environment and for 
historical reasons, laboratory animal models continue to serve as 
the standard in toxicology in order to extrapolate to human out-
comes in the absence of direct human data. But it remains an in-
direct approach and, thus, offers a less than perfect prediction of 
human outcomes. Since neither in vivo animal nor in vitro mech-
anistic data are considered purely predictive of human outcomes 
at this point, various types of mechanistic evidence should be 
combined within an assessment framework to provide robust, 
high-confidence outcomes. AOPs provide such an integrated 
framework but have traditionally been defined through an expert 
review process that can be inconsistent and incomplete. Apply-
ing systematic methodologies to AOP development would result 
in higher certainty in the evidence evaluation underpinning each 
AOP, which would then increase the utility of that AOP for sup-
porting regulatory decisions.
The AOP framework was designed to provide a transparent 
structure to organize knowledge/data and can function as the sci-
entific basis for toxicity extrapolations via the underlying mech-
anisms of toxicity. AOPs can serve as a guide for new assay de-
velopment to fill important gaps and add information about mea-
surable KEs leading to AOs. Retrospective systematic literature 
reviews of in vivo and in vitro mechanistic studies promise a way 
to provide a bridge to human outcomes as well as increase the 
transparency, consistency and objectivity in the development and 
assessment of AOPs as well as the resulting toxicity predictions. 
AOPs combine in vitro or in vivo data by mapping the avail-
able data to the associated KE within the biological mechanism. 
Therefore, the framework naturally integrates different types of 
data, but it does not assess the individual types of data or pro-
vide guidance on how the information from different types of da-
ta should be combined. Systematic methodologies can fill this 
gap within current AOP development practices. The first ideas on 
how to assess the RoB in in vitro (mechanistic) studies and how 
to apply (the domains from) GRADE to AOPs, notably to KERs, 
are being developed, but further research is necessary to establish 
the details of the required tools (Box 1).
As many individuals and organizations do not have the re-
sources to delve into large and growing literature databases, the 
development of broad systematic evidence maps has the potential 
to allow far more researchers to use the scientific literature effec-
tively and to formulate specific questions that can be answered 
by systematic reviews (Wolffe et al., 2019). In order to construct 
such systematic evidence maps, the scientific community needs 
to restructure the way they conduct, report and publish results. At 
the moment, the primary raw data are stripped from experiments 
as they are prepared for publication. These data need to be acces-
sible to anyone and kept as machine-readable meta-data, rather 
than being lost. Systematic evidence maps built on such trans-
parent and complete data would allow researchers to find gaps in 
the knowledge and notice novel associations that were not appar-
ent before. The beauty of the AOP paradigm is that it provides a 
framework for capturing the extracted information, but the chal-
cy (unexplained heterogeneity between individual studies), in-
directness (how well the evidence reflects the question asked), 
imprecision, and publication bias. No additional domains were 
identified. The identified factors strongly suggest that current 
evidence assessment domains used within the GRADE frame-
work (Guyatt et al., 2011) would be sufficient for the evidence 
assessment within AOPs (content validation). 
3.4  AOPs to inform NAM development
The group discussed how AOPs can inform the development of 
NAMs, especially non-animal experimental studies. As a start-
ing point for the discussion, the participants agreed and stressed 
that AOPs are a simplified depiction of complex biology. As a 
consequence, AOPs may leave out KEs, other molecular mech-
anisms leading to the same apical response, or other adverse re-
sponses that are a consequence of the same MIE. Thus, the con-
fidence in a conclusion that a chemical is “toxic” is higher than 
in a conclusion that a chemical is “non-toxic”. 
One important application of an AOP is to support the devel-
opment of IATAs (OECD, 2016). An IATA can be developed 
for different purposes, such as chemical prioritization or re-
placement of animal tests. If AOPs are used to support the de-
velopment of IATAs intended to substitute for in vivo data, the 
nature of the AOP and the KEs measured in the IATA must be 
considered. For example, MIEs may be easier to measure, but 
they are further removed from (and may be less predictive of) 
the AO, while events close to the AO are likely more predictive 
but may be difficult to measure with non-animal methods. Fur-
thermore, if two KEs are highly dependent, the question arises 
if both need to be addressed experimentally (see, e.g., van Vliet 
et al., 2018). While complete understanding of all events in an 
AOP is a goal, organizing evidence in an AOP is informative in 
itself, as it may illustrate gaps in knowledge (Leist et al., 2017). 
A systematic assessment of the relevance of KEs and KERs – 
using evidence-based approaches including a comprehensive 
literature search, critical appraisal of individual studies, and a 
systematic integration of all relevant information – can be used 
to evaluate the certainty/confidence in the understanding of the 
biology linking the mechanism to intermediate responses and 
apical effects. A question raised in this regard was how certain-
ty/confidence in the final decision can be expressed as a func-
tion of confidence in KE, KER, and the NAMs modelling these 
elements. 
The group concluded that AOPs as a representation of 
knowledge may be used to guide development of NAMs to (a) 
strengthen the evidence base for the relevance of KEs, (b) de-
velop batteries of assays to measure a specific type of toxicity 
or non-specific toxicity, (c) target KEs (i.e., nodes) common to 
several AOP, or (d) target specific mechanisms. Development 
of NAMs for use in a regulatory context should consider how 
resulting information is to be used. For example, it may not be 
necessary to develop AOPs that include all possible AOs to con-
clude a chemical may have adverse effects. However, to be con-
fident in a negative identification, the AOP network coverage 
would need to include all relevant biological space.
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help harmonize the terminology, resolve misunderstandings 
and inspire collaboration to collectively advance the fields 
of AOP development and systematic review.
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